Axogen

AXOGEN INC

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Analysts

News

Initiation

Markets

Analyst Ratings

AXGN

BFLY

BPMC

EZPW

PSNL

This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Earnings

Earnings Beats

Large Cap

Mid Cap

Offerings

Small Cap

Events

Trading Ideas

BRKR

KIDS

TMDX

Bruker Corporation (NASDAQ: BRKR) recently announced the acquisition of Dynamic Biosensors GmbH, or DBS, a pioneering company known for its development in biosensors.

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

Macro Economic Events

Economics

PAHC

Bruker Corporation&#39;s (NASDAQ: BRKR) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging.

Here&#39;s Why You Should Retain BRKR Stock in Your Portfolio Now

Axogen Inc

Health Care

Press Releases

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Management

Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AngioDynamics

Artivion

Alphatec Holdings

AtriCure

Beta Bionics

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

Conmed

Delcath Systems

Paragon 28

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

iRadimed

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

LeMaitre Vascular

NeuroPace

NovoCure

Orthofix Medical

Omnicell

Pulse Biosciences

Senseonics Holdings

SI-BONE

Surmodics

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Varex Imaging

Lake Street

Cantor Fitzgerald

Citizens Capital Markets

Canaccord Genuity

Comments

Axogen

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga